Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
What is metformin, the old diabetes drug some people are taking for weight loss?
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...
Cars11h
2020 Chevrolet Malibu
We're not finding any listings in your area. Change your location or shop Cars.com to see more! Your message was sent. You'll receive a response shortly. The Malibu is Chevrolet’s mid-size ...
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Why this newly public biotech could become a force in obesity treatments
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Metsera started at buy at Guggenheim on obesity treatment potential
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
This weight-loss drug stock could deliver a 90% return in 2025
Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31. But analysts are convinced the recent price action is a drop in the bucket compared to where this ...